Abstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
Marcus Couey(Providence Portland Medical Center), Rom S. Leidner(Providence Portland Medical Center), Christopher Paustian(UbiVac (United States)), Tarsem Moudgil(Providence Portland Medical Center), Walter J. Urba(Providence Portland Medical Center), Lessli Rushforth(Providence Portland Medical Center), Matthew Taylor(Oxford Health NHS Foundation Trust), R. Bryan Bell(Takara (United States)), Shawn M. Jensen(Providence Portland Medical Center), Tanisha Christie(Providence Portland Medical Center), Venkatesh Rajamanickam(Cancer Institute (WIA)), Carlo Bifulco(Providence Health & Services), Bernard A. Fox(Oregon Health & Science University), Anne Stadum, Brady Bernard(Providence Portland Medical Center), Traci Hilton(UbiVac (United States)), Yoshinobu Koguchi(Providence Portland Medical Center), Brian Piening(Providence College), Ryan Meng(Providence Portland Medical Center), Hong‐Ming Hu(Viva Biotech (China)), Abigail L. Peterson(Providence Portland Medical Center), William L. Redmond(Providence St. Vincent Medical Center)
Cited by 0
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k